We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-12.76%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$277M
AUM Growth
-$51.6M
Cap. Flow
+$14.5M
Cap. Flow %
5.25%
Top 10 Hldgs %
42.56%
Holding
60
New
17
Increased
8
Reduced
13
Closed
11

Top Buys

Rank Stock Value
1
STXS icon
Stereotaxis
STXS
+$15.6M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$12.5M
3
TVRD
Tvardi Therapeutics
TVRD
+$10.2M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$6.8M
5
QTRX icon
Quanterix
QTRX
+$5.16M

Top Sells

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$9.31M
2
CMRX
Chimerix, Inc.
CMRX
+$6.35M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$5.75M
4
ARVN icon
Arvinas
ARVN
+$4.84M
5
TGTX icon
TG Therapeutics
TGTX
+$3.75M

Sector Composition

Rank Sector Weight
1 Healthcare 99.16%
2 Miscellaneous 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FENC icon
51
Fennec Pharmaceuticals
FENC
$413M
– –
-295,000
Closed -$1.18M
IRWD icon
52
Ironwood Pharmaceuticals
IRWD
$701M
– –
-525,400
Closed -$5.75M
LXRX icon
53
Lexicon Pharmaceuticals
LXRX
$1.03B
– –
-1,480,000
Closed -$9.31M
PLX icon
54
Protalix BioTherapeutics
PLX
$210M
– –
-100,000
Closed -$469K
VKTX icon
55
Viking Therapeutics
VKTX
$3.95B
– –
-400,000
Closed -$3.32M
GRDX
56
GridAI Technologies Corp
GRDX
$28.6M
– –
-1
Closed -$247K
CMRX
57
DELISTED
Chimerix, Inc.
CMRX
– –
-1,470,000
Closed -$6.35M
AIMT
58
DELISTED
Aimmune Therapeutics
AIMT
– –
-130,000
Closed -$2.71M
ARQL
59
DELISTED
Arqule Inc
ARQL
– –
-100,000
Closed -$1.1M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2019 Portfolio in Review

As of Q3 2019, Opaleye Management held 60 positions worth $277M, down 16% from $328M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opaleye Management deployed $14.5M of net new capital in Q3 2019, opening 17 new positions and adding to 8 existing holdings. Its largest new stake was Stereotaxis: 4,070,000 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was TG Therapeutics, an estimated $3.75M trimmed.

  • Opaleye Management's largest Q3 2019 buy was Stereotaxis: 4,070,000 shares worth $14.3M.
  • Opaleye Management added most to Crinetics Pharmaceuticals in Q3 2019, an estimated $3.33M increase.
  • Opaleye Management's biggest Q3 2019 reduction was TG Therapeutics, cutting an estimated $3.75M.
  • Opaleye Management fully exited Lexicon Pharmaceuticals in Q3 2019, selling an estimated $9.31M.
  • Opaleye Management's ten largest holdings make up 43% of its $277M portfolio in Q3 2019.
  • Opaleye Management opened 17 new positions and closed 11 in Q3 2019.
  • Opaleye Management's portfolio value fell 16% quarter-over-quarter to $277M.

Based on Opaleye Management's 13F filing for Q3 2019, filed 14 Nov 2019.